JP2010500398A5 - - Google Patents

Download PDF

Info

Publication number
JP2010500398A5
JP2010500398A5 JP2009524255A JP2009524255A JP2010500398A5 JP 2010500398 A5 JP2010500398 A5 JP 2010500398A5 JP 2009524255 A JP2009524255 A JP 2009524255A JP 2009524255 A JP2009524255 A JP 2009524255A JP 2010500398 A5 JP2010500398 A5 JP 2010500398A5
Authority
JP
Japan
Prior art keywords
vaccine
bulk
item
toxoid
diphtheria
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2009524255A
Other languages
English (en)
Japanese (ja)
Other versions
JP5090452B2 (ja
JP2010500398A (ja
Filing date
Publication date
Priority claimed from GBGB0616306.7A external-priority patent/GB0616306D0/en
Application filed filed Critical
Publication of JP2010500398A publication Critical patent/JP2010500398A/ja
Publication of JP2010500398A5 publication Critical patent/JP2010500398A5/ja
Application granted granted Critical
Publication of JP5090452B2 publication Critical patent/JP5090452B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2009524255A 2006-08-16 2007-08-15 低減された抗原用量を有するブースターワクチンの製造 Expired - Fee Related JP5090452B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0616306.7A GB0616306D0 (en) 2006-08-16 2006-08-16 Vaccines
GB0616306.7 2006-08-16
PCT/IB2007/003255 WO2008020328A2 (en) 2006-08-16 2007-08-15 Manufacture of booster vaccines having reduced antigen doses

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2012200460A Division JP2012236864A (ja) 2006-08-16 2012-09-12 低減された抗原用量を有するブースターワクチンの製造

Publications (3)

Publication Number Publication Date
JP2010500398A JP2010500398A (ja) 2010-01-07
JP2010500398A5 true JP2010500398A5 (enExample) 2011-09-01
JP5090452B2 JP5090452B2 (ja) 2012-12-05

Family

ID=37081096

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2009524255A Expired - Fee Related JP5090452B2 (ja) 2006-08-16 2007-08-15 低減された抗原用量を有するブースターワクチンの製造
JP2012200460A Pending JP2012236864A (ja) 2006-08-16 2012-09-12 低減された抗原用量を有するブースターワクチンの製造

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2012200460A Pending JP2012236864A (ja) 2006-08-16 2012-09-12 低減された抗原用量を有するブースターワクチンの製造

Country Status (7)

Country Link
US (1) US20100158940A1 (enExample)
EP (1) EP2073841B1 (enExample)
JP (2) JP5090452B2 (enExample)
CN (1) CN101522217B (enExample)
ES (1) ES2528665T3 (enExample)
GB (1) GB0616306D0 (enExample)
WO (1) WO2008020328A2 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0822633D0 (en) * 2008-12-11 2009-01-21 Novartis Ag Formulation
ES2443952T3 (es) 2009-09-02 2014-02-21 Novartis Ag Composiciones inmunógenas que incluyen moduladores de la actividad de TLR
CN105999275A (zh) 2010-09-01 2016-10-12 诺华有限公司 免疫增强剂吸附不溶性金属离子
US20140112950A1 (en) 2011-03-02 2014-04-24 Manmohan Singh Combination vaccines with lower doses of antigen and/or adjuvant
CN102526717A (zh) * 2011-11-25 2012-07-04 成都康华生物制品有限公司 一种吸附无细胞百白破联合疫苗的制备方法
US9375471B2 (en) * 2012-03-08 2016-06-28 Glaxosmithkline Biologicals Sa Adjuvanted formulations of booster vaccines
US20150125486A1 (en) * 2012-03-08 2015-05-07 Novartis Ag Adjuvanted formulations of pediatric antigens
CN103908667A (zh) * 2014-04-18 2014-07-09 中国医学科学院医学生物学研究所 吸附无细胞百白破-Sabin株脊髓灰质炎联合疫苗及制备方法
CN104707134A (zh) * 2015-03-27 2015-06-17 成都欧林生物科技股份有限公司 一种无细胞百日破联合疫苗及其制备方法
JP6944946B2 (ja) * 2016-10-20 2021-10-06 Kmバイオロジクス株式会社 低分子化PRPを用いたHibコンジュゲートワクチンの製造方法
KR102426041B1 (ko) * 2017-08-01 2022-07-29 주식회사 녹십자 냉동 및 해동 과정을 포함하는 백일해균 유래 단백질 수득 방법
WO2020165920A1 (en) * 2019-02-12 2020-08-20 Biological E Limited Multivalent vaccine composition
JP7704740B2 (ja) 2019-09-16 2025-07-08 アムジエン・インコーポレーテツド 薬物送達デバイスの外部滅菌の方法
CN111053898B (zh) * 2019-12-26 2023-05-16 北京科兴中维生物技术有限公司 一种疫苗组合物及其应用
CN114748616A (zh) * 2022-05-23 2022-07-15 中国医学科学院医学生物学研究所 一种成人青少年用无细胞百白破联合疫苗及其制备方法
CN119548620B (zh) * 2025-01-23 2025-09-12 康希诺生物股份公司 一种用于预防白喉、百日咳和破伤风的免疫原性组合物、疫苗及其制备方法和应用
CN119524117B (zh) * 2025-01-23 2025-09-23 康希诺生物股份公司 免疫原性组合物、百白破联合疫苗及其制备方法和应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5554125A (en) * 1987-07-08 1996-09-10 Reynolds; David L. Prefilled vial syringe
EP2156845A1 (en) * 1992-05-23 2010-02-24 GlaxoSmithKline Biologicals SA Combined vaccines comprising hepatitis B surface antigen and other antigens
US6696065B1 (en) * 1995-05-04 2004-02-24 Aventis Pastuer Limited Acellular pertussis vaccines and methods of preparation thereof
TR199802783T2 (xx) * 1996-07-02 1999-03-22 Connaught Laboratories Limited �ok de�erli DTP polyo a��lar.
US20010014331A1 (en) * 1996-11-07 2001-08-16 Smithkline Beecham Biologicals S.A. Acellular pertussis vaccine with diphthriae-and tetanus-toxoids
GB9623233D0 (en) * 1996-11-07 1997-01-08 Smithkline Beecham Biolog Vaccine composition
ATE316797T1 (de) * 1997-09-15 2006-02-15 Sanofi Pasteur Msd Verfahren zur herstellung multivalenter impfstoffe
EP1004314A1 (fr) * 1998-11-26 2000-05-31 Pasteur Merieux MSD Vaccin T.d. Polio rappel pour une population vaccinée ou sensibilisée
KR100401423B1 (ko) * 2001-01-10 2003-10-17 주식회사 엘지생명과학 혼합 백신의 제조 방법

Similar Documents

Publication Publication Date Title
JP2010500398A5 (enExample)
JP2015509522A5 (enExample)
JP2015531389A5 (enExample)
Tonnis et al. Improved storage stability and immunogenicity of hepatitis B vaccine after spray-freeze drying in presence of sugars
JP2007507487A5 (enExample)
FI3246044T4 (fi) Neisseria meningitidis rlp2086 -antigeenien stabiileja formulaatioita
Bröker et al. Factors contributing to the immunogenicity of meningococcal conjugate vaccines
JP2018193377A5 (enExample)
JP2020533438A5 (enExample)
JP2012506421A5 (enExample)
Rosenstein et al. Update on Haemophilus influenzae serotype b and meningococcal vaccines
US20220265810A1 (en) Compositions and methods for making and using thermostable immunogenic formulations with increased compatibility of use as vaccines against one or more pathogens
Ruggeberg et al. Immunogenicity and induction of immunological memory of the heptavalent pneumococcal conjugate vaccine in preterm UK infants
JP2011051997A5 (enExample)
HRP20231504T1 (hr) Polisaharidi kapsule iz bakterije streptococcus pneumoniae i njihovi konjugati
RU2008112289A (ru) Множественная вакцинация, включающая менингококки серогруппы с
FI3244917T3 (fi) Immunogeenisiä koostumuksia pneumokokkirokotteissa käytettäväksi
NO20090177L (no) Vaksiner for malaria
JP2015512450A5 (enExample)
CN107810010A (zh) 多价肺炎球菌结合疫苗
Mansour et al. An improved tobacco mosaic virus (TMV)-conjugated multiantigen subunit vaccine against respiratory tularemia
JP2011504487A5 (enExample)
JP2019521102A5 (enExample)
JP2011504535A5 (enExample)
FI3554474T3 (fi) Mikafungiinikoostumuksia